GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » Debt-to-EBITDA

IBER.U (Ibere Pharmaceuticals) Debt-to-EBITDA : -0.17 (As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ibere Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.16 Mil. Ibere Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.00 Mil. Ibere Pharmaceuticals's annualized EBITDA for the quarter that ended in Sep. 2022 was $-0.94 Mil. Ibere Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 was -0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ibere Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

IBER.U' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.15   Med: 0   Max: 0
Current: -0.15

IBER.U's Debt-to-EBITDA is not ranked
in the Diversified Financial Services industry.
Industry Median: 3.94 vs IBER.U: -0.15

Ibere Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Ibere Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals Debt-to-EBITDA Chart

Ibere Pharmaceuticals Annual Data
Trend Dec20 Dec21
Debt-to-EBITDA
N/A -

Ibere Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-EBITDA Get a 7-Day Free Trial - - - -0.28 -0.17

Competitive Comparison of Ibere Pharmaceuticals's Debt-to-EBITDA

For the Shell Companies subindustry, Ibere Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ibere Pharmaceuticals's Debt-to-EBITDA Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Ibere Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ibere Pharmaceuticals's Debt-to-EBITDA falls into.



Ibere Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ibere Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1.004
=0.00

Ibere Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.159 + 0) / -0.936
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2022) EBITDA data.


Ibere Pharmaceuticals  (NYSE:IBER.U) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ibere Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ibere Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ibere Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103
Ibere Pharmaceuticals is a blank check company.
Executives
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes director, 10 percent owner, officer: Chief Operating Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray director, 10 percent owner, officer: Chief Financial Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc 10 percent owner 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines